CRISPR & Cas Genes Market Size Worth USD 21.46 Billion by 2034 | CAGR: 16.5%

The CRISPR & cas genes market size is expected to reach USD 21.46 billion by 2034, according to a new study by Polaris Market Research. The report “CRISPR & Cas Genes Market Size, Share, Trends, Industry Analysis Report By Product (Kits & Enzymes, Libraries), By Service, By Application, By End Use, By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

CRISPR-Cas genes refer to a natural bacterial defense system used for gene editing. The CRISPR sequences guide the Cas enzyme to specific DNA locations to make precise cuts.

CRISPR gene editing offers a sustainable way to improve crops with increasing food demand and environmental challenges. It enables the development of pest-resistant, drought-tolerant, and higher-yielding plants without introducing foreign genes. This precision technology helps create healthier, more nutritious crops that meet consumer and regulatory preferences better than traditional genetically modified organisms (GMOs). Governments and agricultural companies invest heavily in CRISPR-based crop research to improve food security. The expanding use of gene editing in agriculture significantly boosts the demand for CRISPR enzymes, kits, and reagents, driving the market’s growth worldwide.

Bottom of Form

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/crispr-associated-cas-genes-market/request-for-sample

Personalized medicine focuses on tailoring treatments based on an individual’s unique genetic profile. CRISPR technology is crucial for developing gene therapies that target specific genetic mutations causing diseases. More patients seek personalized treatments that improve effectiveness and reduce side effects as awareness about genetic disorders rises. This trend fuels demand for CRISPR-based diagnostics and therapeutics, encouraging companies to invest in research and product development. The market grows as gene editing enables the creation of customized solutions for cancer, rare diseases, and inherited conditions, making personalized medicine a key driver in the CRISPR & Cas genes market.

CRISPR & Cas Genes Market Report Highlights

• The kits & enzymes segment is projected to register a CAGR of 19.1% during the forecast period, owing to their essential role in facilitating gene-editing processes.
• In 2024, the agricultural application segment captured 13.11% of the market revenue, driven by rising demand for improved crop traits such as pest resistance, drought tolerance, and higher yield, which is a key solution to global food security challenges.
• North America led the CRISPR & Cas genes market in 2024, accounting for 45.52% of the global revenue, supported by a robust research ecosystem, significant financial backing, and a highly developed biotechnology sector.
• The Asia Pacific CRISPR & Cas genes market is anticipated to expand at a CAGR of 19.3% during the forecast period, fueled by growing investments in biotechnology research and the strengthening of healthcare infrastructure.
• A few global key market players are Addgene, AstraZeneca, Caribou Biosciences, Inc., Cellectis, CRISPR Therapeutics, Danaher Corporation, Editas Medicine, Inc., Horizon Discovery Group Plc, Mammoth Biosciences, New England BioLabs, Wellcome Trust Sanger Institute, The Innovative Genomics Initiative, Thermo Fisher Scientific, ERS Genomics Ltd, Merck KGaA, Oxford Genetics Limited, and Sherlock Biosciences.

Polaris Market Research has segmented the CRISPR & Cas genes market report based on product, service, application, end use, and region:

By Product (Revenue - USD Billion, 2020–2034)

• Kits & Enzymes
  • Vector-Based Cas
  • DNA-Free Cas
• Libraries
• Design Tool
• Antibodies
• Other Products

By Service (Revenue - USD Billion, 2020–2034)

• Cell Line Engineering
• gRNA Design
• Microbial Gene Editing
• DNA Synthesis

By Application (Revenue - USD Billion, 2020–2034)

• Biomedical
• Agricultural

By End Use (Revenue - USD Billion, 2020–2034)

• Biotechnology & Pharmaceutical Companies
• Academics & Government Research Institutes
• Contract Research Organizations (CROs)

By Regional Outlook (Revenue - USD Billion, 2020–2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa